Healthcare diagnostics company Quest Diagnostics (NYSE:DGX) will be announcing earnings results this Tuesday morning. Here’s ...

Analysts estimate that Quest Diagnostics will report an earnings per share (EPS) of $2.35. Anticipation surrounds Quest Diagnostics's announcement, with investors hoping to hear about both surpassing ...

DGX heads into Q4 earnings with expected revenue and EPS growth, DIS momentum, and benefits from Fresenius assets and ...

Quest Diagnostics (DGX) is scheduled to announce Q4 earnings results on Tuesday, February 10th, before market open. The consensus EPS estimate is $2.36 (+5.8% Y/Y) and the consensus revenue estimate ...

Quest Diagnostics recently unveiled a suite of advanced diagnostics and support services designed to broaden access to lab tests for transplants. Quest hopes to improve testing compliance among ...

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...

Quest beat analysts’ revenue expectations by 3.3% in the third quarter, reporting revenues of $2.82 billion, up 13.2% year-over-year, with an impressive beat of revenue estimates. The company’s ...

Quest Diagnostics completed its acquisition of select assets from Fresenius Medical Care’s laboratory business. As part of the transaction, the Secaucus-based testing provider will now offer ...

Corewell Health Southfield and Quest Diagnostics have completed a previously announced transaction to establish a laboratory ...

A woman thinks her routine blood tests are behind her when she receives an explanation of benefits showing zero patient ...